319 related articles for article (PubMed ID: 35634324)
1. Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics.
Chatterjee B; Thakur SS
Front Immunol; 2022; 13():830990. PubMed ID: 35634324
[TBL] [Abstract][Full Text] [Related]
2. BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.
Tang W-F; Chang Y-H; Lin C-C; Jheng J-R; Hsieh C-F; Chin Y-F; Chang T-Y; Lee J-C; Liang P-H; Lin C-Y; Lin G-H; Cai J-Y; Chen Y-L; Chen Y-S; Tsai S-K; Liu P-C; Yang C-M; Shadbahr T; Tang J; Hsu Y-L; Huang C-H; Wang L-Y; Chen CC; Kau J-H; Hung Y-J; Lee H-Y; Wang W-C; Tsai H-P; Horng J-T
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0095623. PubMed ID: 38446062
[TBL] [Abstract][Full Text] [Related]
3. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Kalil AC; Patterson TF; Mehta AK; Tomashek KM; Wolfe CR; Ghazaryan V; Marconi VC; Ruiz-Palacios GM; Hsieh L; Kline S; Tapson V; Iovine NM; Jain MK; Sweeney DA; El Sahly HM; Branche AR; Regalado Pineda J; Lye DC; Sandkovsky U; Luetkemeyer AF; Cohen SH; Finberg RW; Jackson PEH; Taiwo B; Paules CI; Arguinchona H; Erdmann N; Ahuja N; Frank M; Oh MD; Kim ES; Tan SY; Mularski RA; Nielsen H; Ponce PO; Taylor BS; Larson L; Rouphael NG; Saklawi Y; Cantos VD; Ko ER; Engemann JJ; Amin AN; Watanabe M; Billings J; Elie MC; Davey RT; Burgess TH; Ferreira J; Green M; Makowski M; Cardoso A; de Bono S; Bonnett T; Proschan M; Deye GA; Dempsey W; Nayak SU; Dodd LE; Beigel JH;
N Engl J Med; 2021 Mar; 384(9):795-807. PubMed ID: 33306283
[TBL] [Abstract][Full Text] [Related]
4. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
Zhu W; Chen CZ; Gorshkov K; Xu M; Lo DC; Zheng W
SLAS Discov; 2020 Dec; 25(10):1141-1151. PubMed ID: 32660307
[TBL] [Abstract][Full Text] [Related]
5. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.
Zhang L; Zhou R
J Phys Chem B; 2020 Aug; 124(32):6955-6962. PubMed ID: 32521159
[TBL] [Abstract][Full Text] [Related]
6. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
Hashemian SM; Farhadi T; Velayati AA
Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086
[TBL] [Abstract][Full Text] [Related]
7. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.
Schloer S; Brunotte L; Mecate-Zambrano A; Zheng S; Tang J; Ludwig S; Rescher U
Br J Pharmacol; 2021 Jun; 178(11):2339-2350. PubMed ID: 33825201
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study.
Yasuda Y; Hirayama Y; Uemasu K; Arasawa S; Iwashima D; Takahashi KI
Respir Med Res; 2022 May; 81():100903. PubMed ID: 35316675
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.
Kokic G; Hillen HS; Tegunov D; Dienemann C; Seitz F; Schmitzova J; Farnung L; Siewert A; Höbartner C; Cramer P
Nat Commun; 2021 Jan; 12(1):279. PubMed ID: 33436624
[TBL] [Abstract][Full Text] [Related]
10. Mortality comparision in patients receiving either Remdesivir or Remdesivir plus Baricitinib combination in case of moderate to severe COVID-19 Pneumonia: A retrospective study.
Das D; Mukhopadhyay P; Banerjee D
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443520
[TBL] [Abstract][Full Text] [Related]
11. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19.
Jiang Y; Yin W; Xu HE
Biochem Biophys Res Commun; 2021 Jan; 538():47-53. PubMed ID: 32943188
[TBL] [Abstract][Full Text] [Related]
12. Impact of Remdesivir Incorporation along the Primer Strand on SARS-CoV-2 RNA-Dependent RNA Polymerase.
Naseem-Khan S; Berger MB; Leddin EM; Maghsoud Y; Cisneros GA
J Chem Inf Model; 2022 May; 62(10):2456-2465. PubMed ID: 35435671
[TBL] [Abstract][Full Text] [Related]
13. Remdesivir MD Simulations Suggest a More Favourable Binding to SARS-CoV-2 RNA Dependent RNA Polymerase Mutant P323L Than Wild-Type.
Mohammad A; Al-Mulla F; Wei DQ; Abubaker J
Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34206274
[TBL] [Abstract][Full Text] [Related]
14. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
[TBL] [Abstract][Full Text] [Related]
15. The Binding of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase May Pave The Way Towards the Design of Potential Drugs for COVID-19 Treatment.
Agoni C; Soliman MES
Curr Pharm Biotechnol; 2021; 22(11):1520-1537. PubMed ID: 33109039
[TBL] [Abstract][Full Text] [Related]
16. Theaflavin-3'-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir.
Banerjee A; Kanwar M; Maiti S
Drug Res (Stuttg); 2021 Oct; 71(8):462-472. PubMed ID: 34517419
[TBL] [Abstract][Full Text] [Related]
17. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico.
Elfiky AA; Azzam EB; Shafaa MW
Mol Divers; 2022 Feb; 26(1):171-181. PubMed ID: 33389441
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
[TBL] [Abstract][Full Text] [Related]
19. Remdesivir Strongly Binds to Both RNA-Dependent RNA Polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations.
Nguyen HL; Thai NQ; Truong DT; Li MS
J Phys Chem B; 2020 Dec; 124(50):11337-11348. PubMed ID: 33264025
[TBL] [Abstract][Full Text] [Related]
20. Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models.
Wang Y; Li P; Rajpoot S; Saqib U; Yu P; Li Y; Li Y; Ma Z; Baig MS; Pan Q
Sci Rep; 2021 Dec; 11(1):23465. PubMed ID: 34873274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
